STOK
Price
$12.06
Change
+$0.20 (+1.69%)
Updated
Jul 14 closing price
Capitalization
658.44M
27 days until earnings call
STRO
Price
$0.76
Change
-$0.06 (-7.32%)
Updated
Jul 14 closing price
Capitalization
64.5M
23 days until earnings call
Interact to see
Advertisement

STOK vs STRO

Header iconSTOK vs STRO Comparison
Open Charts STOK vs STROBanner chart's image
Stoke Therapeutics
Price$12.06
Change+$0.20 (+1.69%)
Volume$488.34K
Capitalization658.44M
Sutro Biopharma
Price$0.76
Change-$0.06 (-7.32%)
Volume$374.85K
Capitalization64.5M
STOK vs STRO Comparison Chart in %
Loading...
STOK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
STOK vs. STRO commentary
Jul 15, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is STOK is a Buy and STRO is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 15, 2025
Stock price -- (STOK: $12.06 vs. STRO: $0.76)
Brand notoriety: STOK and STRO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: STOK: 85% vs. STRO: 35%
Market capitalization -- STOK: $658.44M vs. STRO: $64.5M
STOK [@Biotechnology] is valued at $658.44M. STRO’s [@Biotechnology] market capitalization is $64.5M. The market cap for tickers in the [@Biotechnology] industry ranges from $305.86B to $0. The average market capitalization across the [@Biotechnology] industry is $2.43B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

STOK’s FA Score shows that 1 FA rating(s) are green whileSTRO’s FA Score has 1 green FA rating(s).

  • STOK’s FA Score: 1 green, 4 red.
  • STRO’s FA Score: 1 green, 4 red.
According to our system of comparison, STOK is a better buy in the long-term than STRO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

STOK’s TA Score shows that 3 TA indicator(s) are bullish while STRO’s TA Score has 6 bullish TA indicator(s).

  • STOK’s TA Score: 3 bullish, 5 bearish.
  • STRO’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, STRO is a better buy in the short-term than STOK.

Price Growth

STOK (@Biotechnology) experienced а +3.17% price change this week, while STRO (@Biotechnology) price change was +3.09% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +10.48%. For the same industry, the average monthly price growth was +21.25%, and the average quarterly price growth was +31.32%.

Reported Earning Dates

STOK is expected to report earnings on Nov 11, 2025.

STRO is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+10.48% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
STOK($658M) has a higher market cap than STRO($64.5M). STOK YTD gains are higher at: 9.338 vs. STRO (-58.495). STOK has higher annual earnings (EBITDA): 40.3M vs. STRO (-203.18M). STOK has more cash in the bank: 357M vs. STRO (249M). STOK has less debt than STRO: STOK (2.35M) vs STRO (21.4M). STOK has higher revenues than STRO: STOK (191M) vs STRO (66.4M).
STOKSTROSTOK / STRO
Capitalization658M64.5M1,020%
EBITDA40.3M-203.18M-20%
Gain YTD9.338-58.495-16%
P/E Ratio14.71N/A-
Revenue191M66.4M288%
Total Cash357M249M143%
Total Debt2.35M21.4M11%
FUNDAMENTALS RATINGS
STOK vs STRO: Fundamental Ratings
STOK
STRO
OUTLOOK RATING
1..100
692
VALUATION
overvalued / fair valued / undervalued
1..100
53
Fair valued
26
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
41100
PRICE GROWTH RATING
1..100
4164
P/E GROWTH RATING
1..100
27100
SEASONALITY SCORE
1..100
n/a75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

STRO's Valuation (26) in the Pharmaceuticals Major industry is in the same range as STOK (53) in the null industry. This means that STRO’s stock grew similarly to STOK’s over the last 12 months.

STRO's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as STOK (100) in the null industry. This means that STRO’s stock grew similarly to STOK’s over the last 12 months.

STOK's SMR Rating (41) in the null industry is somewhat better than the same rating for STRO (100) in the Pharmaceuticals Major industry. This means that STOK’s stock grew somewhat faster than STRO’s over the last 12 months.

STOK's Price Growth Rating (41) in the null industry is in the same range as STRO (64) in the Pharmaceuticals Major industry. This means that STOK’s stock grew similarly to STRO’s over the last 12 months.

STOK's P/E Growth Rating (27) in the null industry is significantly better than the same rating for STRO (100) in the Pharmaceuticals Major industry. This means that STOK’s stock grew significantly faster than STRO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
STOKSTRO
RSI
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
82%
Momentum
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
86%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
76%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 6 days ago
86%
Bullish Trend 6 days ago
80%
Declines
ODDS (%)
Bearish Trend 13 days ago
84%
Bearish Trend 9 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
77%
Aroon
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
STOK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PBAM57.451.35
+2.41%
Private Bancorp of America, Inc.
ARRKF0.740.01
+1.18%
ARRAS MINERALS CORP.
CPYYY8.550.05
+0.60%
Centrica Plc
MCOIF6.61N/A
N/A
MultiChoice Group Limited
DENI15.93N/A
N/A
Denali Bancorp Inc

STOK and

Correlation & Price change

A.I.dvisor indicates that over the last year, STOK has been loosely correlated with IDYA. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if STOK jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To STOK
1D Price
Change %
STOK100%
+1.69%
IDYA - STOK
52%
Loosely correlated
+0.44%
IMNM - STOK
51%
Loosely correlated
-1.50%
NRIX - STOK
51%
Loosely correlated
+2.01%
RNA - STOK
50%
Loosely correlated
+6.74%
TRML - STOK
49%
Loosely correlated
+5.45%
More

STRO and

Correlation & Price change

A.I.dvisor indicates that over the last year, STRO has been loosely correlated with ALGS. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if STRO jumps, then ALGS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To STRO
1D Price
Change %
STRO100%
+0.29%
ALGS - STRO
44%
Loosely correlated
+3.95%
PDSB - STRO
40%
Loosely correlated
-0.81%
BEAM - STRO
40%
Loosely correlated
+0.05%
TCRX - STRO
40%
Loosely correlated
+6.08%
ATXS - STRO
40%
Loosely correlated
+3.92%
More